Opinion|Videos|January 17, 2025
Practice Pearls for Managing Patients With Prurigo Nodularis
Author(s)Shawn Kwatra, MD, FAAD
A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Based on our discussion today, what key insights or new perspectives could you share regarding treatment considerations for systemic therapies for prurigo nodularis?
- What take-home messages or practice pearls do you have for clinicians treating patients with prurigo nodularis?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
